Ackman: Plan to Discuss Drug Prices With Valeant Board

The transcript discusses pricing strategies, focusing on significant price increases for certain drugs and their impact on returns. It questions the sustainability of such a business model, especially concerning investor expectations. The conversation highlights Valiant's diverse business segments, emphasizing that only a small portion of their revenue is affected by these pricing actions.

What aspects of Valiant's business model does the speaker highlight as attractive?

How does the speaker describe the pricing of consumer products made by the company?